



SARS COV-2 monoclonal antibody therapy is available at Kaleida Health as an outpatient treatment for patients at high risk of deterioration who are either COVID positive or as post exposure prophylaxis. Use of monoclonal antibody therapy shows a 70-87% reduction in COVID-19-related hospitalization or all-cause death through day 29 in patients with mild to moderate disease.*

Indication	COVID Positive	Post-Exposure Prophylaxis
Criteria	High risk of progression to severe disease who do not require new or increasing oxygen requirements*	Not fully vaccinated OR Not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (for example individuals with and immunocompromising condition or those taking immunosuppressive medications*)
COVID Test	Positive test at the time of referral	N/A
Treatment Window	Within 10 days of symptom onset	As soon as possible after exposure to a COVID positive individual consistent with close contact criteria per CDC

* www.regencov.com/hcp or www.covid19.lilly.com/bam-ete/hcp



Direct patients to the UBMD Emergency Medicine Telemedicine link below for referral to a Kaleida Health COVID monoclonal clinic



<https://kaleida-health.inquicker.com/facility/kaleida-emergency-telemedicine>

For patient with significant mobility issues that might make access to the clinics difficult, may consider referral to the VNA for home infusion or subcutaneous injection. Do not use telemedicine for this option; contact the VNA directly:

VNA Referral

Phone: (716) 630-8100

Fax: (716) 630-8700